Novotech, the global full-service clinical Contract Research Organization (CRO), has published its latest whitepaper, offering in-depth analysis and emerging trends and advancements within the rapidly evolving field of cell and gene therapies. The report provides critical insights into the growth of clinical trials, innovations and strategic opportunities, shaping the future of this field.
Key Highlights from the Report:
- Global Clinical Trial Expansion:
- Over 1,500 drug candidates in development across phases 0 to III.
- CAR-T therapies account for 32% of the pipeline, primarily targeting hematological cancers.
- The global trial landscape experienced a 32.5% growth from 2019 to 2023, with Asia-Pacific leading in trial activity (44% of all trials).
- Oncology Focus:
- CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and hematological malignancies.
- Significant attention on gastrointestinal tract and lung cancers, as well as hematological cancers like diffuse large B-cell lymphoma (DLBCL).
- Geographic Leadership:
- Asia-Pacific: Strong growth driven by China, which leads with 56% of the region's cell and gene trials.
- North America: The U.S. dominates with 85% of the trials.
- Europe: The UK, Spain, and Germany are key players.
- Technological Advancements:
- AI and Contract Development and Manufacturing Organizations (CDMOs) are transforming the cell and gene therapy landscape, improving manufacturing efficiency and trial scalability.
- Patient Recruitment Trends:
- Faster recruitment in Asia-Pacific (16.07 months) compared to the U.S. (21.15 months), with the region showing higher enrollment efficiency.
- Investment Growth:
- A significant rise in venture capital for cell and gene therapies peaked in 2021, with sustained funding for start-ups and growth-stage companies.
Novotech’s whitepaper highlights the significant potential of cell and gene therapies, particularly in oncology, and outlines opportunities for increased collaboration in global clinical trials.
Download the full report to explore the complete clinical landscape and discover how Novotech can accelerate your research efforts.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
For more information or to speak to an expert team member visit www.Novotech-CRO.com